The purpose of this talk is to summarize current imaging practices in urologic oncology applications including prostate cancer, urothelial cancer, and renal cell carcinoma. Recent advances in nuclear medicine for prostate cancer imaging are summarized including novel tracer agents for PET. Prostate MRI, CT and MR urography, along with conventional CT imaging are discussed in the context of urologic malignancies.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/31/23.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: There are no Planning Committee disclosures to declare. Speakers Conflict of Interest Disclosure: There are no speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared. Accreditation Statement: The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be able to summarize recent advancements in the imaging of urologic cancer, including PET and MR imaging of prostate cancer, CT and MR imaging of urothelial cancer, and the v2019 Bosniak classification for cystic renal masses.